Drug Profile

HS 001

Alternative Names: HS-001; HS-001 CS; HS-005; Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension; NN-9003

Latest Information Update: 22 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Heartseed Inc.
Class Cell therapies; Gene therapies; Heart failure therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Heart failure

Most Recent Events

01 Jan 2026 Heartseed plans a phase I/II EMERALD trial for Heart failure and Ischaemic heart disorders (Intracardiac) in January 2026 (NCT07347197)
11 Sep 2023 Efficacy and adverse events data from a Phase I/II LAPiS trial in Heart failure released by Heartseed
25 May 2023 Heartseed announces intention to launch HS 001 for Heart failure

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com